| Ytd | -64.94% | |
| 1y | -90.86% |
| Open | 0.24 | Prev Close | 0.23 | Low | 0.23 | High | 0.24 | Mkt Cap | 7.70M |
| Vol | 162.42K | Avg Vol | 2.12M | EPS | -1.83 | P/E | -0.13 | Forward P/E | -1.49 |
| Beta | 0.40 | Short Ratio | 1.69 | Inst. Own | 53.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.51 | 200-d Avg | 1.53 | 1yr Est | 13.00 |
VTGN News
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in S
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fased
Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-pat
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical tr
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YO
NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is invest
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical comp
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Vistagen Therap
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biophar
New York, New York--(Newsfile Corp. - April 20, 2026) - Kuehn Law, PLLC, a shareholder litigation la
VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) crossed below its 50 day moving average
Shares of VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) passed above its 50 day movin
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
New class action for Vistagen (VTGN) urges investors to seek recovery for alleged securities fraud v
On Tuesday, 838 companies hit new 52-week lows.
On Friday, 137 stocks made new 52-week lows.
During Tuesday's session, 539 stocks hit new 52-week lows.
Wednesday's session saw 269 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Monday, 149 companies reached new 52-week lows.
Gainers Synthetic Biologics, Inc. (NYSE: SYN) shares climbed 100% to close at $1.00 on Tuesday af
This morning 77 companies reached new 52-week highs.
Friday's session saw 466 companies set new 52-week highs.